Perrigo’s impressive second quarter saw the company complete several key milestones in its transition to an entirely self-care pharmaceutical firm, closing its multi-billion-dollar takeover of HRA Pharma and completing its first branded Rx-to-OTC switchover of Nasonex 24HR in the US. In high spirits on the firms Q2 results call, company president and CEO Murray Kessler thanked his team for “a truly remarkable quarter.”
The firm achieved sales of $1.1bn during the quarter, an increase of 14.3% – or 20.2% on a constant-currency basis...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?